NasdaqGS:BCRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. More Details


Snowflake Analysis

Slightly overvalued with limited growth.


Similar Companies

Share Price & News

How has BioCryst Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BCRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: BCRX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.


Market Performance


7 Day Return

-7.4%

BCRX

-7.7%

US Biotechs

-4.0%

US Market


1 Year Return

252.2%

BCRX

30.1%

US Biotechs

46.6%

US Market

Return vs Industry: BCRX exceeded the US Biotechs industry which returned 24.2% over the past year.

Return vs Market: BCRX exceeded the US Market which returned 36.2% over the past year.


Shareholder returns

BCRXIndustryMarket
7 Day-7.4%-7.7%-4.0%
30 Day13.3%-13.4%-4.1%
90 Day44.8%-4.7%3.3%
1 Year252.2%252.2%32.1%30.1%49.8%46.6%
3 Year98.1%98.1%10.4%4.8%47.8%38.4%
5 Year297.7%297.7%48.8%37.8%116.6%92.6%

Long-Term Price Volatility Vs. Market

How volatile is BioCryst Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioCryst Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: BCRX ($11.15) is trading below our estimate of fair value ($79.72)

Significantly Below Fair Value: BCRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BCRX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BCRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BCRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BCRX has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.


Next Steps

Future Growth

How is BioCryst Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

56.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCRX's revenue (42.4% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: BCRX's revenue (42.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCRX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioCryst Pharmaceuticals performed over the past 5 years?

-23.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BCRX is currently unprofitable.

Growing Profit Margin: BCRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BCRX is unprofitable, and losses have increased over the past 5 years at a rate of 23.8% per year.

Accelerating Growth: Unable to compare BCRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).


Return on Equity

High ROE: BCRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is BioCryst Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: BCRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BCRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BCRX has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BCRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BCRX has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 24.6% each year.


Next Steps

Dividend

What is BioCryst Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BCRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BCRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BCRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BCRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Jon Stonehouse (59 yo)

14.17yrs

Tenure

US$2,284,297

Compensation

Mr. Jon P. Stonehouse has been the Chief Executive Officer and Executive Director of BioCryst Pharmaceuticals, Inc. at Shionogi & Co., Ltd. since joining in January 8, 2007 and also has been its President ...


CEO Compensation Analysis

Compensation vs Market: Jon's total compensation ($USD2.28M) is below average for companies of similar size in the US market ($USD3.62M).

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Jon Stonehouse
CEO, President & Director14.17yrsUS$2.28m0.44%
$ 8.7m
William Sheridan
Chief Medical Officer & Senior VP12.67yrsUS$1.07m0.0065%
$ 127.9k
Yarlagadda Babu
Senior Vice President of Drug Discovery7.42yrsUS$1.08m0.10%
$ 2.0m
Megan Sniecinski
Senior VP & Chief Business Officer1.67yrsUS$2.18m0.025%
$ 501.8k
Anthony Doyle
Senior VP & CFO0.92yrno data0.030%
$ 602.1k
Michael Jones
Executive Director of Finance & Principal Accounting Officer1.17yrsno data0.00048%
$ 9.5k
John Bluth
Senior Vice President of Investor Relations & Corporate Communicationsno datano datano data
Alane Barnes
Senior VP14.5yrsUS$1.33m0.061%
$ 1.2m
Robert Stoner
Vice President of Human Resourcesno datano datano data
Elliott Berger
Senior Vice President of Regulatory Affairsno datano datano data
Charles Gayer
Senior VP & Chief Commercial Officer1.17yrsno data0.072%
$ 1.4m

4.5yrs

Average Tenure

52yo

Average Age

Experienced Management: BCRX's management team is considered experienced (4.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jon Stonehouse
CEO, President & Director14.17yrsUS$2.28m0.44%
$ 8.7m
Stephen Aselage
Independent Director2.17yrsUS$280.19k0.018%
$ 351.1k
Robert Ingram
Independent Chairman3.83yrsUS$154.09k0.042%
$ 836.5k
Alan Levin
Independent Director1.08yrsno datano data
Kenneth Lee
Independent Director9.75yrsUS$134.09k0.0086%
$ 170.0k
George Abercrombie
Independent Director9.42yrsUS$129.71k0.0056%
$ 111.4k
Helen Thackray
Independent Director1.5yrsUS$95.30kno data
Theresa Heggie
Independent Director2.25yrsUS$119.71k0.0078%
$ 154.4k
Nancy Hutson
Independent Director9.17yrsUS$134.09k0.036%
$ 722.1k

3.8yrs

Average Tenure

65yo

Average Age

Experienced Board: BCRX's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.2%.


Top Shareholders

Company Information

BioCryst Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioCryst Pharmaceuticals, Inc.
  • Ticker: BCRX
  • Exchange: NasdaqGS
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.979b
  • Shares outstanding: 177.52m
  • Website: https://www.biocryst.com

Number of Employees


Location

  • BioCryst Pharmaceuticals, Inc.
  • 4505 Emperor Boulevard
  • Suite 200
  • Durham
  • North Carolina
  • 27703
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 1994
BO1DB (Deutsche Boerse AG)YesCommon StockDEEURMar 1994
BCRX *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNMar 1994

Biography

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of a...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/03/09 00:01
End of Day Share Price2021/03/08 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.